[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"e55830f0-b06e-4c54-bab4-91b6f117fa14","acronym":"","url":"https://clinicaltrials.gov/study/NCT04582487","created_at":"2021-01-18T21:51:58.830Z","updated_at":"2024-07-02T16:35:20.351Z","phase":"","brief_title":"Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL","source_id_and_acronym":"NCT04582487","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP","pipe":"","alterations":" ","tags":["KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-02-07"},{"id":"979632e5-5844-47cd-bb14-5dedd6d753fe","acronym":"TRABTRAP","url":"https://clinicaltrials.gov/study/NCT05597917","created_at":"2022-10-28T13:57:00.387Z","updated_at":"2024-07-02T16:35:25.392Z","phase":"Phase 3","brief_title":"tTF-NGR Randomized Study - STS","source_id_and_acronym":"NCT05597917 - TRABTRAP","lead_sponsor":"Universität Münster","biomarkers":" BCOR • ANPEP","pipe":"","alterations":" ","tags":["BCOR • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-22"},{"id":"9eac4268-8e45-4c25-be18-2972151ca188","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494167","created_at":"2021-01-18T12:01:22.240Z","updated_at":"2024-07-02T16:35:45.346Z","phase":"Phase 1","brief_title":"Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)","source_id_and_acronym":"NCT02494167","lead_sponsor":"Baylor College of Medicine","biomarkers":" KIT • WT1 • CD33 • ANPEP","pipe":"","alterations":" ","tags":["KIT • WT1 • CD33 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-06-19"},{"id":"2f9fa5a1-f8a1-4926-9315-c7558aef01b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04446130","created_at":"2021-01-18T21:23:46.117Z","updated_at":"2024-07-02T16:36:43.887Z","phase":"Phase 3","brief_title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","source_id_and_acronym":"NCT04446130","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" KIT • CD33 • CD34 • ITGAM • ANPEP","pipe":"","alterations":" ","tags":["KIT • CD33 • CD34 • ITGAM • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2020-06-24"},{"id":"307f73d9-02fe-4164-bff8-b7e3cc8feaa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04429438","created_at":"2021-01-18T21:20:00.358Z","updated_at":"2024-07-02T16:36:44.235Z","phase":"Phase 1/2","brief_title":"Multi-CAR-T Cells Targeting B Cell Lymphomas","source_id_and_acronym":"NCT04429438","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD19 • CD79B • CD22 • CD70 • ANPEP","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD79B • CD22 • CD70 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e multi-CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"b1f11587-1e6a-45c2-ba3a-84eabd15cc73","acronym":"INO-VATE","url":"https://clinicaltrials.gov/study/NCT01564784","created_at":"2021-01-18T06:37:59.936Z","updated_at":"2024-07-02T16:37:04.082Z","phase":"Phase 3","brief_title":"A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01564784 - INO-VATE","lead_sponsor":"Pfizer","biomarkers":" CD22 • IL3RA • ANPEP","pipe":" | ","alterations":" CD22 expression","tags":["CD22 • IL3RA • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Besponsa (inotuzumab ozogamicin) • mitoxantrone • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 326","initiation":"Initiation: 08/02/2012","start_date":" 08/02/2012","primary_txt":" Primary completion: 03/08/2016","primary_completion_date":" 03/08/2016","study_txt":" Completion: 01/04/2017","study_completion_date":" 01/04/2017","last_update_posted":"2019-01-09"},{"id":"8b50b7e9-7468-4a63-8f8b-5dddd813e679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00945815","created_at":"2021-01-18T03:40:26.168Z","updated_at":"2024-07-02T16:37:16.636Z","phase":"Phase 2","brief_title":"S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00945815","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD22 • CD33 • CD4 • ANPEP","pipe":"","alterations":" ","tags":["CD22 • CD33 • CD4 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • clofarabine • Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2017-11-06"}]